Home > Notice & News   
 
.    24 1/2
Subject
Hyundai Pharm, MIRAP ER Tab, Parkinson¡¯s disease drug, launch
Content
Hyundai Pharm, MIRAP ER Tab, Parkinson¡¯s disease drug, launch

Hyundai, Expects Synergistic effect through CNS products reinforcement



Hyundai Pharm (President, Yeong Hak Kim) stated Hyundai will launch Parkinson disease drug Mirap ER (Pramipexole, Original: Mirapex)

Mirap ER (Pramipexole), Parkinsons disease treatment, is used as monotherapy for the early treatment and also combination treatment with levodopa is also possible for ongoing Parkinson¡¯s disease patients. Its administration is much convenient now where it is taken once a day compare to three times day of traditional regimen.

Mirap ER is a non-ergot dopamine agonist and the first new generic as a sustained release form of pramipexole in Korea. It improves the Parkinson¡¯s symptoms such as dyskinesia symptoms by binding to dopamine receptors in the striatum increasing dopamine activity.
Date
2014-03-28
   
 
No.
Subject
Date
27
2015-11-09
26
2015-10-14
24
2015-09-02
23
2015-06-25
22
2015-05-12
21
2015-04-17
20
2015-03-26
19
2014-12-12
18
2014-12-05
17
2014-11-13
16
2014-08-19
15
2014-06-30
14
2014-06-05
2014-03-28
12
2014-02-18
     
 
main_footer